News & Updates
Filter by Specialty:
Show Multimedia Only

First-line durvalumab plus tremelimumab safe to use in unresectable HCC
05 Sep 2025
byStephen Padilla
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
05 Sep 2025
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
05 Sep 2025
byAudrey Abella
Supplemental breast cancer (BC) imaging techniques may help detect early cancers that standard mammograms may have missed in women with dense breasts, according to interim results from the BRAID* trial.